Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2024 | $6.00 → $3.00 | Outperform → Sector Perform | RBC Capital Mkts |
6/21/2024 | $5.00 → $6.00 | Sector Perform → Outperform | RBC Capital Mkts |
4/8/2024 | $6.00 | Buy | BTIG Research |
4/5/2024 | $6.00 | Neutral → Buy | CL King |
1/12/2024 | $14.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
10/13/2023 | $32.00 → $3.00 | Buy → Underperform | BofA Securities |
8/17/2023 | Neutral | CL King | |
11/11/2022 | $23.00 | Outperform | RBC Capital Mkts |
RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously
RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously
BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00
S-8 - Outset Medical, Inc. (0001484612) (Filer)
8-K - Outset Medical, Inc. (0001484612) (Filer)
SD - Outset Medical, Inc. (0001484612) (Filer)
SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma
SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on
SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margi
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SAN JOSE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 46th annual Healthcare conference on Wednesday, June 11, 2025, at 11:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc.Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hem
SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective immediately. In addition to leading Finance, Ms. Gaeta will have responsibility for Outset's Information Technology and Human Resources organizations. She succeeds Nabeel Ahmed who is leaving the company to pursue other opportunities. "Renee brings deep financial and leadership experience to Outset with a proven track record from her roles at publicly traded medical-device growth companie
SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)